Aducanumab: Articles & Publications
Read all AAN articles and publication content pertaining to aducanumab (Aduhelm).
Neurology®
Performing Cost-Effectiveness Analyses to Support Policy Making: Key Lessons From the Assessment of Aducanumab (Neurology®) | January 12, 2022
Aducanumab, Amyloid Lowering, and Slowing of Alzheimer Disease (Neurology®) | July 7, 2021
Prescribing Aducanumab in the Face of Meager Efficacy and Real Risks (Neurology®) | July 7, 2021
Clinical Efficacy, Drug Safety and Surrogate Endpoints: Has Aducanumab Met All of Its Expectations? (Neurology®) | July 7, 2021
Neurology®podcast
Aducanumab: What About the Patient? (Neurology® podcast) | November 2, 2021
Aducanumab and the Business of Alzheimer Disease (Neurology® podcast) | October 26, 2021
Dr. Daniel Gibbs on his Battle with Alzheimer's (Neurology®podcast) | July 5, 2021
Special Report on Aducanumab Approval: A Pulitzer Prize-winning Journalist's Perspective (Neurology®podcast) | June 24, 2021
Special Report on Aducanumab Approval: Discussion with Cognitive Behavioral Specialists (Neurology®podcast) | June 19, 2021
Special Report on Aducanumab Approval: Steve Pearson of ICER Discusses the Economic and Clinical Impact (Neurology®podcast) | June 17, 2021
Neurology Today®
What FDA’s Accelerated Approval of Aducanumab Means for Other Neurology Drugs (Neurology Today®) | July 20, 2021
Aducanumab—Academic Memory Programs Brace for the Tough Questions (Neurology Today®) | July 13, 2021
Dementia Experts on Why the FDA Approval of Aducanumab for Alzheimer’s Gets Mixed Grades (Neurology Today®) | June 9, 2021
Other
CMS releases proposed coverage determination for aducanumab. Individuals can provide comments by February 10 | January 11, 2022
Practical Considerations in the Administration of Aducanumab for the Neurologist (Neurology® Clinical Practice) | December 15, 2021
Cost Effectiveness of Aducanumab (Neurology Minute® podcast) | August 31, 2021
[Patient Resource] New Alzheimer’s Drug Aducanumab Stirs Controversy and Hope (Brain & Life®) | August 2021
CMS solicits public comments by August 11 on proposed coverage of aducanumab | July 12, 2021
FDA revises aducanumab label to narrow the eligible patients | July 8, 2021